Ritter: RP-G28 has could become first FDA-approved lactose intolerance drug

Ritter Pharmaceuticals believes its Phase II-stage drug candidate RP-G28, its first-in-class treatment for lactose intolerance, has the potential to become the first FDA-approved drug for the condition.